Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05269381
Title	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Mayo Clinic
Indications	Advanced Solid Tumor cervical cancer hepatocellular carcinoma transitional cell carcinoma skin squamous cell carcinoma renal cell carcinoma gastric adenocarcinoma lung non-small cell carcinoma Merkel cell carcinoma triple-receptor negative breast cancer gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma melanoma endometrial carcinoma
Therapies	Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Mayo Clinic in Florida	Recruiting	Jacksonville	Florida	32224-9980	United States	Details

*Shaded cells indicate that there was no data available from clincialtrials.gov for the field